Apellis Aims New Pegcetacoplan Data At Market, Not Regulators
Executive Summary
The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.
You may also be interested in...
Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.